RedHill Biopharma Ltd. (NASDAQ:RDHL)
| Market Cap | $883.14K-72.7% |
| Revenue (ttm) | $0+16.0% |
| Net Income | -$6.10M+33.3% |
| EPS | $0.00+85.0% |
| Shares Out | 3.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,254 |
| Open | $0.31 |
| Previous Close | $0.32 |
| Day's Range | $0.28 - $0.34 |
| 52-Week Range | $0.28 - $1.60 |
| Beta | 4.87 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Mar 18, 2027 |
About RDHL
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 18, 2027Earnings report
$RDHL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RDHL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RDHL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RDHL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RDHL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RDHL from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from RDHL’s recent data — informational, not investment advice
